Advanced Therapies – Opportunities and Challenges

14th November, London


Click on the name of the speaker to download the slide deck

Keynote Session: “The Future of Advanced Therapies”

  • Peter Goodfellow, Scientific Advisor, Abingworth
    “Regenerating the Future, Again”
  • Lord James O’Shaughnessy, Parliamentary Under Secretary of State for Health (Lords), UK Government
  • Ian Campbell, Director for Health and Life Sciences, Innovate UK
    “Innovate UK Supporting Research Development & Manufacturing in Advanced Therapies”
  • Christian K Schneider, Director, National Institute for Biological Standards and Control (NIBSC)
    “Advanced Therapies – regulatory challenges”

Building Effective R&D Partnerships to Accelerate ATMPs

  • Seigo Izumo, Senior Vice President for Regenerative Medicine, Takeda Pharmaceuticals
  • Eduardo Bravo, Chief Executive Officer, TiGenix; EBE President
  • Qasim Rafiq, Senior Lecturer (Associate Professor) in Bioprocessing of Regenerative, Cellular and Gene Therapies, UCL
  • Keith Thompson, Chief Executive Officer, Cell and Gene Therapy Catapult

ATMPs as Cures – The Opportunities and Challenges for Europe

  • Michaël Hocquemiller, Scientific Director, Lysogene
    “Pioneering gene therapies for CNS disorders”
  • Adrien Lemoine, VP Business Development & Operations, Orchard Therapeutics
    “Overcoming the complex challenges associated with the development of ex vivo gene therapies for rare diseases”
  • Karen Hodgkin, Chief Operating Officer, Cell Medica
    “Cell Medica: Novel approaches for the treatment of Solid Tumours”
  • James McBlane, CAT Alternate Member, Preclinical Assessor, UK Medicines and Healthcare Products Regulatory Agency (MHRA)
    “Partnering well together – creating a global ecosystem for advanced therapies”

R&D and Commercialisation 2020 – Maximising the Value of European Innovation

  • Magda Papadaki, Head of Product and Process Innovation, Association of the British Pharmaceutical Industry (ABPI)
  • Barbara Freischem, Executive Director, European Biopharmaceutical Enterprises (EBE)
  • Deborah Morrison, Senior Scientific Adviser, National Institute for Health and Care Excellence (NICE)
  • Michael Stein, Chief Executive Officer and Chairman, Oxstem Ltd

Supported by:

Click edit button to change this text.